## SEQUENCE LISTING

```
<110> AplaGen GmbH
<120> New Peptides
<130> 050398wo Me/FM
<140> PCT/EP2005/050742
<141> 2005-02-21
<150> US 60/545906
<151> 2004-02-20
<160> 8
<170> PatentIn Ver. 2.1
<210> 1
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 1
Val Tyr Lys Ser Pro Asn Ala Tyr Thr Leu Phe Ser
                  5
<210> 2
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 2
Arg Pro Glu Pro Gln Gly Ala Tyr Leu Glu Gln Gly
                  5
<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 3
Asn Ser Ser Tyr Ser Pro Ser Leu Leu Glu Ser Gly
```

1 5 10

```
<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 4
Asp Gln Tyr Ile Gln Gln Ala His Arg Ser His Ile
 1
                  5
<210> 5
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 5
Gln Gly Leu Pro Ala Pro Gln Ser Tyr Ser Arg Ile
                  5
<210> 6
<211> 12
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 6
Lys Gln Ala Ser Asn Leu Thr Asp Met His Tyr Pro
 1
                  5
<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:synthetic
      peptide
<400> 7
Ala Gln Pro Asn Trp Thr Ser Leu Arg Ser Leu Pro
                  5
```

```
<210> 8
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:synthetic peptide
<400> 8
His Val Asn Pro His Leu His Val His Ala Trp Asp
1 5 10
```

- 3 -